Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Viville, S.
Right arrow Articles by Ménézo, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Viville, S.
Right arrow Articles by Ménézo, Y.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 17, No. 2, 261-263, February 2002
© 2002 European Society of Human Reproduction and Embryology


OPINION

Human embryo research in France

Stéphane Viville1,2,4 and Yves Ménézo3

1 Service de Biologie de la Reproduction SIHCUS-CMCO, 19, rue Louis Pasteur BP120, 67303 Schiltigheim, 2 Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS/INSERM/ULP, 1, rue Laurent Fries, BP 163, 67404 Illkirch Cedex, C.U. de Strasbourg and 3 Laboratoire Marcel Mérieux, 1 Rue Laborde 69500 BRON, France

Abstract

The French law on bioethics, voted upon in July 1994, is going to be revised. This is the occasion for France to reconsider its position concerning research on human embryos, which is currently prohibited in France, as it is in Germany, Switzerland and Austria. However, such research is authorised in other European countries such as the UK, Spain, Belgium, Italy and The Netherlands. The establishment of human embryonic stem (ES) cells has reopened the debate in France because of their potential in human therapy. Indeed, ES cells, derived from early embryos (5–6 days old), preserve in vitro a pluripotent character, and they could provide an infinite source of different tissues that could be used in replacement therapy. This consists of ES cells differentiated in vitro into the desired tissues or cell types and grafted into the patient. The use of human ES cells in replacement therapy raises the major problem of graft rejection. One of the proposed solutions would be to carry out a `therapeutic cloning' and to derive ES cells from the embryos obtained in this way. We do consider that, for the moment, the interest of the cloning study lies mainly in the understanding of the mechanisms responsible for reprogramming the nuclei. This research can be performed first on animal models.

France is now thinking to allow human embryo research. We present here the French law proposed on human embryo research. French government is proposing to allow research exclusively on frozen supernumerary embryos, which no longer have any parental or adoption potential. Creation of human embryos for research purposes will still be prohibited. However, allowance of studies on human cloning in order to realise therapeutic cloning is mentioned in the proposal. We think that allowing research in humans on therapeutic cloning is premature and contradicts the prohibition of the creation of human embryos for research.

Key words: embryonic stem cells/ethics/human embryo research/therapeutic cloning

Notes

4 To whom correspondence should be addressed. E-mail: viville{at}igbmc.u-strasbg.fr


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.